The therapeutic community is abuzz with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 receptor that’s demonstrating significant efficacy in clinical trials for managing obesity. Unlike some current weight loss solutions, retatrutide appears to provide a greater substantial reduction in body mass and improve metabolic function,